Skip to main content

Tamiflu Side Effects

Generic name: oseltamivir

Medically reviewed by Drugs.com. Last updated on Sep 25, 2023.

Note: This document provides detailed information about Tamiflu Side Effects associated with oseltamivir. Some dosage forms listed on this page may not apply specifically to the brand name Tamiflu.

Applies to oseltamivir: oral capsule, oral powder for suspension.

Common side effects of Tamiflu

Some side effects of oseltamivir may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • diarrhea
  • nausea
  • vomiting

Less common

  • abdominal or stomach pain
  • bloody nose or unexplained nosebleeds (occurs mainly in children)
  • burning, dry, or itching eyes (mainly in children)
  • dizziness
  • ear disorder (occurs mainly in children)
  • excessive tearing of the eyes (mainly in children)
  • redness, pain, or swelling of the eye or eyelid (mainly in children)
  • trouble with sleeping

Rare

  • pale skin
  • troubled breathing
  • unusual bleeding or bruising

Incidence not known

  • blurred vision
  • cracked, dry, or scaly skin
  • dry mouth
  • flushed, dry skin
  • mood or mental changes
  • skin rash that is encrusted, scaly, and oozing

Serious side effects of Tamiflu

Along with its needed effects, oseltamivir (the active ingredient contained in Tamiflu) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking oseltamivir:

Less common

  • phlegm-producing cough
  • wheezing

Rare

  • abdominal or stomach cramps or tenderness
  • arm, back, or jaw pain
  • bloating
  • chest pain or discomfort
  • diarrhea, watery and severe, which may also be bloody
  • drooling
  • facial swelling
  • fast or irregular heartbeat
  • hoarseness
  • increased thirst
  • pain
  • shortness of breath
  • unusual weight loss

Incidence not known

  • blistering, peeling, or loosening of the skin
  • convulsions (seizures)
  • dark urine
  • difficulty with swallowing
  • fainting
  • fast, slow, or irregular heartbeat
  • hives or welts
  • itching, puffiness, or swelling of the eyelids or around the eyes, face, lips, or tongue
  • joint or muscle pain
  • light-colored stools
  • loss of bladder control
  • loss of consciousness
  • muscle spasm or jerking of all extremities
  • red skin lesions, often with a purple center
  • red, irritated eyes
  • skin rash or itching over the entire body
  • sores, ulcers, or white spots in the mouth or on the lips
  • sweating
  • upper right abdominal or stomach pain
  • yellow eyes and skin

For healthcare professionals

Applies to oseltamivir: oral capsule, oral powder for reconstitution.

General

The most common side effects were nausea and vomiting.

The most common side effects reported with this drug during studies for the treatment of influenza were nausea, vomiting, and headache; the most common side effects reported in prophylaxis studies were nausea, vomiting, headache, and pain. Most side effects were reported on a single occasion, occurred on the first or second day of therapy, and resolved spontaneously within 1 to 2 days.[Ref]

Nervous system

Side effects with similar or higher incidence among placebo patients included dizziness and vertigo.[Ref]

Gastrointestinal

Side effects with similar or higher incidence among placebo patients included diarrhea, abdominal pain, upper abdominal pain, and dyspepsia.[Ref]

Respiratory

Side effects with similar or higher incidence among placebo patients included cough, nasal congestion, sore throat, rhinorrhea, bronchitis, sinusitis, nasopharyngitis, upper respiratory tract infections, and influenza.[Ref]

Psychiatric

Influenza can be associated with various neurologic and behavioral symptoms (including hallucinations, delirium, abnormal behavior), with fatal outcomes in some cases; such events may occur with encephalitis or encephalopathy but can occur without obvious severe disease. There are postmarketing reports (mostly in Japan) of delirium and abnormal behavior leading to injury, with fatal outcomes in some cases, in influenza patients using this drug. Although frequency is unknown, based on usage, these events appear uncommon. These events were primarily reported in pediatric patients, often with abrupt onset and rapid resolution. The contribution of this drug to such events has not been established.

Side effects with similar or higher incidence among placebo patients included insomnia.[Ref]

Other

Side effects with similar or higher incidence among placebo patients included fatigue, pyrexia, influenza-like illness, and pain in limb.[Ref]

Dermatologic

Side effects with similar or higher incidence among placebo patients included herpes simplex.[Ref]

Musculoskeletal

Side effects with similar or higher incidence among placebo patients included back pain, arthralgia, and myalgia.[Ref]

Genitourinary

Side effects with similar or higher incidence among placebo patients included dysmenorrhea.

Ocular

Hepatic

Hypersensitivity

Cardiovascular

Metabolic

Hematologic

References

1. (2001) "Product Information. Tamiflu (oseltamivir)." Roche Laboratories

2. Hayden FG, Atmar RL, Schilling M, et al. (1999) "Use of selective oral neura minidase inhibitor oseltamivir to prevent influenza." N Engl J Med, 341, p. 1336-43

3. Cox NJ, Hughes JM (1999) "New options for the prevention of influenza." N Engl J Med, 341, p. 1387-8

4. Treanor JJ, Hayden FG, Vrooman PS, et al. (2000) "Efficacy and safety of the oral neuramidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial." JAMA, 283, p. 1016-24

5. He G, Massarella J, Ward P (1999) "Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802." Clin Pharmacokinet, 37, p. 471-84

6. Bardsley-Elliot A, Noble S (1999) "Oseltamivir." Drugs, 58, p. 851-60

7. Montalto NJ, Gum KD, Ashley JV (2000) "Updated treatment for influenza A and B." Am Fam Physician, 62, p. 2467-76

8. Nicholson KG, Aoki FY, Osterhaus AD, et al. (2000) "Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial." Lancet, 355, p. 1845-50

9. Dreitlein WB, Maratos J, Brocavich J (2001) "Zanamivir and oseltamivir: Two new options for the treatment and prevention of influenza." Clin Ther, 23, p. 327-55

10. Welliver R, Monto AS, Carewicz O, et al. (2001) "Effectiveness of oseltamivir in preventing influenza in household contacts." JAMA, 285, p. 748-54

11. McClellan K, Perry CM (2001) "Oseltamivir: a review of its use in influenza." Drugs, 61, p. 263-83

12. Snell P, Dave N, Wilson K, et al. (2005) "Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate." Br J Clin Pharmacol, 59, p. 598-601

13. Moscona A (2005) "Neuraminidase inhibitors for influenza." N Engl J Med, 353, p. 1363-73

14. (2006) "Antiviral drugs prophylaxis and treatment of influenza." Med Lett Drugs Ther, 48, p. 87-8

15. McNicholl IR, McNicholl JJ (2001) "Neuraminidase inhibitors: zanamivir and oseltamivir." Ann Pharmacother, 35, p. 57-70

16. Cerner Multum, Inc. "Australian Product Information."

17. Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A (2006) "Antivirals for influenza in healthy adults: systematic review." Lancet, 367, p. 303-13

18. (2007) "New concerns about oseltamivir." Lancet, 369, p. 1056

19. Strong M, Burrows J, Redgrave P (2009) "A/H1N1 pandemic. Oseltamivir's adverse events." BMJ, 339, b3249

20. Jefferson T, Jones M, Doshi P, Del Mar C (2009) "Possible harms of oseltamivir-a call for urgent action." Lancet, 374, p. 1312-3

21. (2012) "Antiviral drugs for influenza." Med Lett Drugs Ther, 54, p. 1-3

22. Anekthananon T, Pukritayakamee S, Ratanasuwan W, et al. (2013) "Oseltamivir and inhaled zanamivir as influenza prophylaxis in Thai health workers: a randomized, double-blind, placebo-controlled safety trial over 16 weeks." J Antimicrob Chemother, 68, p. 697-707

23. (2012) "Antiviral drugs for influenza 2012-2013." Med Lett Drugs Ther, 54, p. 97-8

24. Cerner Multum, Inc. "UK Summary of Product Characteristics."

25. Hama R (2007) "Oseltamivir's adverse reactions: Fifty sudden deaths may be related to central suppression." BMJ, 335, p. 59

26. Ho LN, Chung JP, Choy KL (2010) "Oseltamivir-induced mania in a patient with H1N1." Am J Psychiatry, 167, p. 350

27. Abe M, Smith J, Urae A, Barrett J, Kinoshita H, Rayner CR (2006) "Pharmacokinetics of Oseltamivir in Young and Very Elderly Subjects (October)." Ann Pharmacother

28. Hankey GJ (2000) "Clopidogrel and thrombotic thrombocytopenic purpura." Lancet, 356, p. 269-70

Frequently asked questions

Further information

Tamiflu side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.